Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Meta analysis
 
Feedback
Home
c19early.org COVID-19 treatment researchHH-120HH-120 (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

    
  
HH-120 for COVID-19
2 studies from 31 scientists
345 patients in 1 country
Statistically significant lower risk for cases and viral clearance.
2 studies (both from the same team) show statistically significant improvements.
COVID-19 HH-120 studies. Feb 2024. c19early.org
0 0.5 1 1.5+ All studies 49% Cases 76% Viral clearance 20% Prophylaxis 76% Late 20% FavorsHH-120 Favorscontrol
Feb 26
Covid Analysis HH-120 for COVID-19: real-time meta analysis of 2 studies
Statistically significant lower risk is seen for cases and viral clearance. 2 studies (both from the same team) show statistically significant improvements. Meta analysis using the most serious outcome reported shows 49% [-60‑8..
Dec 6
2023
Song et al., Journal of Medical Virology, doi:10.1002/jmv.29275 Nasal spray of an IgM‐like ACE2 fusion protein HH‐120 prevents SARS‐CoV‐2 infection: Two investigator‐initiated postexposure prophylaxis trials
76% fewer symptomatic cases (p=0.02) and 58% fewer cases (p=0.03). RCT 269 participants showing significantly reduced risk of infection and symptomatic infection with IgM-like ACE2 fusion protein HH-120 nasal spray used as post-exposure prophylaxis. Participants self-administered HH-120 or placebo 5-10 t..
May 25
2023
Song et al., Journal of Medical Virology, doi:10.1002/jmv.28805 Nasal spray of an IgM‐like ACE2 fusion protein HH‐120 accelerates SARS‐CoV‐2 clearance: A single‐center propensity score‐matched cohort study
20% faster viral clearance (p=0.001). PSM analysis of 65 HH-120 patients and 103 controls contemporaneously hospitalized in the same hospital, showing faster viral clearance with HH-120 treatment, with improved results for patients with higher baseline viral load.
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit